AstraZeneca PLC ADR (AZN): Price and Financial Metrics

AstraZeneca PLC ADR (AZN): $66.70

-0.11 (-0.16%)

POWR Rating

Component Grades














  • Sentiment is the dimension where AZN ranks best; there it ranks ahead of 92.1% of US stocks.
  • AZN's strongest trending metric is Quality; it's been moving down over the last 179 days.
  • AZN ranks lowest in Momentum; there it ranks in the 8th percentile.

AZN Stock Summary

  • With a market capitalization of $204,365,947,714, Astrazeneca Plc has a greater market value than 98.91% of US stocks.
  • With a price/earnings ratio of 1,777.1, Astrazeneca Plc P/E ratio is greater than that of about 99.45% of stocks in our set with positive earnings.
  • In terms of volatility of its share price, AZN is more volatile than only 5.65% of stocks we're observing.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Astrazeneca Plc are NVS, BMY, MRK, NFLX, and TXN.
  • AZN's SEC filings can be seen here. And to visit Astrazeneca Plc's official web site, go to

AZN Valuation Summary

  • AZN's EV/EBIT ratio is 29.1; this is 0.68% lower than that of the median Healthcare stock.
  • Over the past 243 months, AZN's price/sales ratio has gone up 2.7.
  • Over the past 243 months, AZN's price/sales ratio has gone up 2.7.

Below are key valuation metrics over time for AZN.

Stock Date P/S P/B P/E EV/EBIT
AZN 2021-08-31 5.2 9.8 40.6 29.1
AZN 2021-08-30 5.2 9.8 40.8 29.2
AZN 2021-08-27 5.2 9.8 40.8 29.3
AZN 2021-08-26 5.2 9.8 40.9 29.3
AZN 2021-08-25 5.2 9.8 40.8 29.2
AZN 2021-08-24 5.2 9.8 40.8 29.2

AZN Growth Metrics

    Its 3 year price growth rate is now at 31.18%.
  • Its 2 year cash and equivalents growth rate is now at 13.58%.
  • The 5 year price growth rate now stands at 75.14%.
AZN's revenue has moved up $12,651,000,000 over the prior 70 months.

The table below shows AZN's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 37,417 5,963 115
2021-12-31 37,417 5,963 115
2021-09-30 32,816 6,343 1,466
2021-06-30 29,528 6,446 3,768
2021-03-31 27,583 6,594 3,956
2020-12-31 26,617 4,799 3,144

AZN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • AZN has a Quality Grade of B, ranking ahead of 78.56% of graded US stocks.
  • AZN's asset turnover comes in at 0.438 -- ranking 104th of 681 Pharmaceutical Products stocks.
  • CLVS, HSKA, and FLXN are the stocks whose asset turnover ratios are most correlated with AZN.

The table below shows AZN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.438 0.765 0.209
2021-03-31 0.431 0.792 0.231
2020-12-31 0.429 0.801 0.205
2020-09-30 0.427 0.801 0.174
2020-06-30 0.433 0.800 0.161
2020-03-31 0.422 0.794 0.126

AZN Stock Price Chart Interactive Chart >

Price chart for AZN

AZN Price/Volume Stats

Current price $66.70 52-week high $71.70
Prev. close $66.81 52-week low $53.63
Day low $66.20 Volume 3,289,759
Day high $67.14 Avg. volume 7,046,590
50-day MA $65.25 Dividend yield 1.36%
200-day MA $62.28 Market Cap 206.69B

AstraZeneca PLC ADR (AZN) Company Bio

AstraZeneca plc engages in the discovery, development, and commercialization of prescription medicines for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection, and neuroscience diseases worldwide. The company was founded in 1992 and is based in London, the United Kingdom.

AZN Latest News Stream

Event/Time News Detail
Loading, please wait...

AZN Latest Social Stream

Loading social stream, please wait...

View Full AZN Social Stream

Latest AZN News From Around the Web

Below are the latest news stories about Astrazeneca Plc that investors may wish to consider to help them evaluate AZN as an investment opportunity.

AstraZeneca, GSK''s COVID-19 Therapies Lose Efficacy Against Omicron''s Subvariants

The FDA authorized an increased dose in the case of AstraZeneca Plc''s (NASDAQ: AZN ) pre-exposure prophylaxis drug Evusheld (tixagevimab and cilgavimab). "Based on the most recent information and data available, Evusheld may be less active against certain Omicron subvariants. The dosing regimen was revised because available data indicate that a higher dose of Evusheld may be more likely to prevent infection by the COVID-19 Omicron subvariants BA.1 and BA.1.1 than the originally authorized Evusheld dose," the FDA said … Full story available on

Benzinga | February 25, 2022

AstraZeneca PLC (NASDAQ:AZN) Has Reached A Distance Of 22.97% From Its Low, So Is It Poised For More Gains?

In recent trading session, AstraZeneca PLC (NASDAQ:AZN) saw 2.54 million shares changing hands at last check today with its beta currently measuring 0.48. Company’s recent per share price level of $60.34 trading at $2.21 or 3.80% at last check today assigns it a market valuation of $182.26B. That most recent trading price of AZN’s stock … AstraZeneca PLC (NASDAQ:AZN) Has Reached A Distance Of 22.97% From Its Low, So Is It Poised For More Gains? Read More »

Marketing Sentinel | February 25, 2022

Ionis (IONS) Q4 Earnings & Revenues Beat Estimates, Stock Up

Teaser: Ionis (IONS) beats Q4 earnings and sales estimates. Stock rises.

Yahoo | February 25, 2022

Pharma Stock Roundup: GSK, SNY Face Pipeline Setbacks, AZN Cancer Study Meets Goals

Glaxo (GSK) and Sanofi (SNY) announce pipeline setbacks. AstraZeneca's (AZN) HER2-low metastatic breast cancer study on Enhertu succeeds.

Yahoo | February 25, 2022

Biohaven Further Deepens Its Neurology Pipeline With Bristol Myers, Knopp Biosciences Deals

View more earnings on BHVNSee more from BenzingaBlood Clot Risk After First AstraZeneca COVID-19 Shot Very Small - UK Study ShowsModerna Adds Three New mRNA-Based Development Programs To Its Pipeline© 2022 Benzinga does not provide investment advice. All rights reserved.

Yahoo | February 25, 2022

Read More 'AZN' Stories Here

AZN Price Returns

1-mo -0.30%
3-mo 6.07%
6-mo 11.90%
1-year 16.17%
3-year 62.47%
5-year 165.93%
YTD 17.17%
2021 19.66%
2020 3.06%
2019 35.58%
2018 13.77%
2017 33.10%

AZN Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full AZN Dividend History

Continue Researching AZN

Here are a few links from around the web to help you further your research on Astrazeneca Plc's stock as an investment opportunity:

Astrazeneca Plc (AZN) Stock Price | Nasdaq
Astrazeneca Plc (AZN) Stock Quote, History and News - Yahoo Finance
Astrazeneca Plc (AZN) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.5466 seconds.